Dr. Hoeffler made a pivotal contribution in 2000 with his scientific paper entitled “Spontaneous Cell Sorting of Fibroblasts and Keratinocytes Creates an Organotypic Human Skin Equivalent”, advancing the concept of triggering cells to migrate into correct position, rather than attempting to position them using ‘inkjet’ printing technology, or consecutive layering. We received extensive criticism at the time, but now it’s used as the platform for organ creation in some of the best research. Whenever taxpayers are asked to foot the bill for medical innovation, they justifiably expect improved treatments, but the hype exceeds the reality. The following video is one mother’s agony at the inability to help her son recover from a spinal cord injury using stem cells, representing the majority of patient experiences. Public support for science is awarded to institutions, with multi-million dollar budgets, and not the scientists, who write the grants. Expensive buildings, administrative costs, equipment and supplies leave little for anyone actually conducting experiments to improve patient care. Senior scientists write grants and network. As a consequence, large investments result in little technological innovation.

HOF follows these guidelines to advance our stem cell program in ways better suited for providing useful patient care:

1. Skin is the first target organ of choice because it is superficial therefore cells can easily be added and taken away.

2. Only minimal regulations should apply to skin grafting with stem cells.

3. Success should be determined by the accuracy of microarchitecture, not just expensive analysis.

4. Patient success with one organ should fast-track applications in other organs by the same institution.

5. Intellectual property from public funding must be owned by the public, while company IP paid for by investors is kept private.